M. Angela Cenci

cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum.

Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.

Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective.

Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.

Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.

The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.

Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.

Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.

Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.

Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.

L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.

Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.

Rodent models of treatment-induced motor complications in Parkinson's disease.

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.

Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.

Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.

Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.

Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease.

Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations.

A model of GDNF gene therapy in mice with 6-Hydroxydopamine lesions: time course of Neurorestorative effects and ERK1/2 activation.

Bad news for neuroprotective therapies in PD?

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.

Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism.

Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.

Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.

Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.

Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5.

Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.

A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.

Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.

Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia.

Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached?

Increased CSF biomarkers of angiogenesis in Parkinson disease.

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.

Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.

Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.

Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.

Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.

Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.

Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.

CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.

Translating scientific advances into disease-modifying therapies for Parkinson's Disease.

Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia.

Animal models of l-dopa-induced dyskinesia in Parkinson's disease.

mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.

On the neuronal circuitry mediating L-DOPA-induced dyskinesia.

Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.

Significance and Translational Value of High-Frequency Cortico-Basal Ganglia Oscillations in Parkinson's Disease.

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease.

Seeding of protein aggregation causes cognitive impairment in rat model of cortical synucleinopathy.

Dyskinesia matters.

D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease.

The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications.

Animal models for preclinical Parkinson's research: An update and critical appraisal.

Preface: The evolving scenario of Parkinson's research.

Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini.